Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse. Lenalidomide alone or in combination with rituximab has been shown to be active in relap...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Chiappella, Annalisa, Tucci, Alessandra, Castellino, Alessia, Pavone, Vincenzo, Baldi, Ileana, Carella, Angelo Michele, Orsucci, Lorella, Zanni, Manuela, Salvi, Flavia, Liberati, Anna Marina, Gaidano, Gianluca, Bottelli, Chiara, Rossini, Bernardo, Perticone, Sonia, De Masi, Pasqualina, Ladetto, Marco, Ciccone, Giovannino, Palumbo, Antonio, Rossi, Giuseppe, Vitolo, Umberto
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2013
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815174/
https://ncbi.nlm.nih.gov/pubmed/23812930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.085134
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires